191 related articles for article (PubMed ID: 16176921)
41. Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice.
Zhou HM; Bolon I; Nichols A; Wohlwend A; Vassalli JD
Cancer Res; 2001 Feb; 61(3):970-6. PubMed ID: 11221892
[TBL] [Abstract][Full Text] [Related]
42. A keratin 15 containing stem cell population from the hair follicle contributes to squamous papilloma development in the mouse.
Li S; Park H; Trempus CS; Gordon D; Liu Y; Cotsarelis G; Morris RJ
Mol Carcinog; 2013 Oct; 52(10):751-9. PubMed ID: 22431489
[TBL] [Abstract][Full Text] [Related]
43. 12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mice expressing epidermal-targeted v-fos induces rasHA-activated papillomas and carcinomas without p53 mutation: association of v-fos expression with promotion and tumor autonomy.
Greenhalgh DA; Wang XJ; Eckhardt JN; Roop DR
Cell Growth Differ; 1995 May; 6(5):579-86. PubMed ID: 7544154
[TBL] [Abstract][Full Text] [Related]
44. Oxymetholone: II. Evaluation in the Tg-AC transgenic mouse model for detection of carcinogens.
Holden HE; Stoll RE; Blanchard KT
Toxicol Pathol; 1999; 27(5):507-12. PubMed ID: 10528629
[TBL] [Abstract][Full Text] [Related]
45. Genetic interaction between the unstable v-Ha-RAS transgene (Tg.AC) and the murine Werner syndrome gene: transgene instability and tumorigenesis.
Leder A; Lebel M; Zhou F; Fontaine K; Bishop A; Leder P
Oncogene; 2002 Sep; 21(43):6657-68. PubMed ID: 12242664
[TBL] [Abstract][Full Text] [Related]
46. Co-operation between follicular ornithine decarboxylase and v-Ha-ras induces spontaneous papillomas and malignant conversion in transgenic skin.
Smith MK; Trempus CS; Gilmour SK
Carcinogenesis; 1998 Aug; 19(8):1409-15. PubMed ID: 9744537
[TBL] [Abstract][Full Text] [Related]
47. Cooperation between v-fos and v-rasHA induces autonomous papillomas in transgenic epidermis but not malignant conversion.
Greenhalgh DA; Quintanilla MI; Orengo CC; Barber JL; Eckhardt JN; Rothnagel JA; Roop DR
Cancer Res; 1993 Nov; 53(21):5071-5. PubMed ID: 7693330
[TBL] [Abstract][Full Text] [Related]
48. Oral administration of dimethylvinyl chloride increases frequency of forestomach papillomas in Tg.AC mice.
Cannon RE; Graves S; Spalding JW; Trempus CS; Tennant RW
Mol Carcinog; 2000 Dec; 29(4):229-35. PubMed ID: 11170261
[TBL] [Abstract][Full Text] [Related]
49. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis.
Tiano HF; Loftin CD; Akunda J; Lee CA; Spalding J; Sessoms A; Dunson DB; Rogan EG; Morham SG; Smart RC; Langenbach R
Cancer Res; 2002 Jun; 62(12):3395-401. PubMed ID: 12067981
[TBL] [Abstract][Full Text] [Related]
50. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels.
Larcher F; Robles AI; Duran H; Murillas R; Quintanilla M; Cano A; Conti CJ; Jorcano JL
Cancer Res; 1996 Dec; 56(23):5391-6. PubMed ID: 8968091
[TBL] [Abstract][Full Text] [Related]
51. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype.
Weaver JL; Contrera JF; Rosenzweig BA; Thompson KL; Faustino PJ; Strong JM; Ellison CD; Anderson LW; Prasanna HR; Long-Bradley PE; Lin KK; Zhang J; Sistare FD
Toxicol Pathol; 1998; 26(4):532-40. PubMed ID: 9715512
[TBL] [Abstract][Full Text] [Related]
52. Identification of genes and gene ontology processes critical to skin papilloma development in Tg.AC transgenic mice.
Dang H; Trempus C; Malarkey DE; Wei SJ; Humble M; Morris RJ; Tennant RW
Mol Carcinog; 2006 Feb; 45(2):126-40. PubMed ID: 16329151
[TBL] [Abstract][Full Text] [Related]
53. TGF alpha is dispensable for skin tumorigenesis in Tg.AC mice.
Humble MC; Szczesniak CJ; Luetteke NC; Spalding JW; Cannon RE; Hansen LA; Lee DC; Tennant RW
Toxicol Pathol; 1998; 26(4):562-9. PubMed ID: 9715516
[TBL] [Abstract][Full Text] [Related]
54. Altered glucocorticoid receptor expression and function during mouse skin carcinogenesis.
Budunova IV; Carbajal S; Kang H; Viaje A; Slaga TJ
Mol Carcinog; 1997 Mar; 18(3):177-85. PubMed ID: 9115588
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of the Tg.AC transgenic mouse assay for testing the human carcinogenic potential of pharmaceuticals--practical pointers, mechanistic clues, and new questions.
Sistare FD; Thompson KL; Honchel R; DeGeorge J
Int J Toxicol; 2002; 21(1):65-79. PubMed ID: 11936901
[TBL] [Abstract][Full Text] [Related]
56. 26-Week dermal oncogenicity study evaluating pure trans-capsaicin in Tg.AC hemizygous mice (FBV/N).
Chanda S; Erexson G; Frost D; Babbar S; Burlew JA; Bley K
Int J Toxicol; 2007; 26(2):123-33. PubMed ID: 17454252
[TBL] [Abstract][Full Text] [Related]
57. Glucocorticoid receptor functions as a potent suppressor of mouse skin carcinogenesis.
Budunova IV; Kowalczyk D; Pérez P; Yao YJ; Jorcano JL; Slaga TJ
Oncogene; 2003 May; 22(21):3279-87. PubMed ID: 12761498
[TBL] [Abstract][Full Text] [Related]
58. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness.
Thompson KL; Rosenzweig BA; Sistare FD
Toxicol Pathol; 1998; 26(4):548-55. PubMed ID: 9715514
[TBL] [Abstract][Full Text] [Related]
59. Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes.
Ando K; Saitoh A; Hino O; Takahashi R; Kimura M; Katsuki M
Cancer Res; 1992 Feb; 52(4):978-82. PubMed ID: 1737360
[TBL] [Abstract][Full Text] [Related]
60. Dermal carcinogenicity in transgenic mice: effect of vehicle on responsiveness of hemizygous Tg.AC mice to phorbol 12-myristate 13-acetate (TPA).
Stoll RE; Furst SM; Stoltz JH; Lilly PD; Mennear JH
Toxicol Pathol; 2001; 29(5):535-40. PubMed ID: 11695570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
